CETP inhibitor (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CETP inhibitor" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

10doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

1acs.org

1,248^th place

1,104^th place

1forbes.com

54^th place

48^th place

1marketwatch.com

1,303^rd place

808^th place

1merck.com

6,464^th place

5,671^st place

1handle.net

102^nd place

76^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

acs.org

cen.acs.org

Carmen Drahl (February 2012). "The Cholesterol Bet". Chemical & Engineering News. 90 (8): 13–20. doi:10.1021/cen-09008-cover.

clinicaltrials.gov

"Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-12-02.

doi.org

Tall AR (March 2007). "CETP inhibitors to increase HDL cholesterol levels". The New England Journal of Medicine. 356 (13): 1364–1366. doi:10.1056/NEJMe078029. PMID 17387130.
Joy TR, Hegele RA (August 2008). "The failure of torcetrapib: what have we learned?". British Journal of Pharmacology. 154 (7): 1379–1381. doi:10.1038/bjp.2008.248. PMC 2492099. PMID 18536741.
Rennings AJ, Stalenhoef A (October 2008). "JTT-705: is there still future for a CETP inhibitor after torcetrapib?". Expert Opinion on Investigational Drugs. 17 (10): 1589–1597. doi:10.1517/13543784.17.10.1589. PMID 18808319. S2CID 5781222.
Carmen Drahl (February 2012). "The Cholesterol Bet". Chemical & Engineering News. 90 (8): 13–20. doi:10.1021/cen-09008-cover.
Filippatos TD, Kei A, Elisaf MS (September 2017). "Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?". Diseases. 5 (4): 21. doi:10.3390/diseases5040021. PMC 5750532. PMID 28961179.
Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. (September 2017). "Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease". The New England Journal of Medicine. 377 (13): 1217–1227. doi:10.1056/NEJMoa1706444. PMID 28847206.
Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, et al. (August 2015). "Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial". Lancet. 386 (9992): 452–460. doi:10.1016/S0140-6736(15)60158-1. hdl:1887/117246. PMID 26047975. S2CID 7540974.
Barkowski RS, Frishman WH (May 2018). "HDL metabolism and CETP inhibition". Cardiology in Review. 16 (3): 154–162. doi:10.1097/CRD.0b013e31816a3b60. PMID 18414186. S2CID 25024920.
Keene D, Price C, Shun-Shin MJ, Francis DP (July 2014). "Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients". BMJ. 349: g4379. doi:10.1136/bmj.g4379. PMC 4103514. PMID 25038074.
Tardif JC, Rhéaume E, Lemieux Perreault LP, Grégoire JC, Feroz Zada Y, Asselin G, et al. (April 2015). "Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib". Circulation: Cardiovascular Genetics. 8 (2): 372–382. doi:10.1161/CIRCGENETICS.114.000663. PMID 25583994.

forbes.com

Larry Husten (May 2012). "Roche Terminates Development Of CETP Inhibitor Dalcetrapib". Forbes.

handle.net

hdl.handle.net

Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, et al. (August 2015). "Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial". Lancet. 386 (9992): 452–460. doi:10.1016/S0140-6736(15)60158-1. hdl:1887/117246. PMID 26047975. S2CID 7540974.

marketwatch.com

"Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease". Oct 12, 2015.

merck.com

investors.merck.com

"Merck Provides Update on Anacetrapib Development Program". Merck.com. October 11, 2017. Retrieved January 4, 2018.

nih.gov

pubmed.ncbi.nlm.nih.gov

Tall AR (March 2007). "CETP inhibitors to increase HDL cholesterol levels". The New England Journal of Medicine. 356 (13): 1364–1366. doi:10.1056/NEJMe078029. PMID 17387130.
Joy TR, Hegele RA (August 2008). "The failure of torcetrapib: what have we learned?". British Journal of Pharmacology. 154 (7): 1379–1381. doi:10.1038/bjp.2008.248. PMC 2492099. PMID 18536741.
Rennings AJ, Stalenhoef A (October 2008). "JTT-705: is there still future for a CETP inhibitor after torcetrapib?". Expert Opinion on Investigational Drugs. 17 (10): 1589–1597. doi:10.1517/13543784.17.10.1589. PMID 18808319. S2CID 5781222.
Filippatos TD, Kei A, Elisaf MS (September 2017). "Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?". Diseases. 5 (4): 21. doi:10.3390/diseases5040021. PMC 5750532. PMID 28961179.
Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. (September 2017). "Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease". The New England Journal of Medicine. 377 (13): 1217–1227. doi:10.1056/NEJMoa1706444. PMID 28847206.
Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, et al. (August 2015). "Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial". Lancet. 386 (9992): 452–460. doi:10.1016/S0140-6736(15)60158-1. hdl:1887/117246. PMID 26047975. S2CID 7540974.
Barkowski RS, Frishman WH (May 2018). "HDL metabolism and CETP inhibition". Cardiology in Review. 16 (3): 154–162. doi:10.1097/CRD.0b013e31816a3b60. PMID 18414186. S2CID 25024920.
Keene D, Price C, Shun-Shin MJ, Francis DP (July 2014). "Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients". BMJ. 349: g4379. doi:10.1136/bmj.g4379. PMC 4103514. PMID 25038074.
Tardif JC, Rhéaume E, Lemieux Perreault LP, Grégoire JC, Feroz Zada Y, Asselin G, et al. (April 2015). "Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib". Circulation: Cardiovascular Genetics. 8 (2): 372–382. doi:10.1161/CIRCGENETICS.114.000663. PMID 25583994.

ncbi.nlm.nih.gov

Joy TR, Hegele RA (August 2008). "The failure of torcetrapib: what have we learned?". British Journal of Pharmacology. 154 (7): 1379–1381. doi:10.1038/bjp.2008.248. PMC 2492099. PMID 18536741.
Filippatos TD, Kei A, Elisaf MS (September 2017). "Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?". Diseases. 5 (4): 21. doi:10.3390/diseases5040021. PMC 5750532. PMID 28961179.
Keene D, Price C, Shun-Shin MJ, Francis DP (July 2014). "Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients". BMJ. 349: g4379. doi:10.1136/bmj.g4379. PMC 4103514. PMID 25038074.

semanticscholar.org

api.semanticscholar.org

Rennings AJ, Stalenhoef A (October 2008). "JTT-705: is there still future for a CETP inhibitor after torcetrapib?". Expert Opinion on Investigational Drugs. 17 (10): 1589–1597. doi:10.1517/13543784.17.10.1589. PMID 18808319. S2CID 5781222.
Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, et al. (August 2015). "Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial". Lancet. 386 (9992): 452–460. doi:10.1016/S0140-6736(15)60158-1. hdl:1887/117246. PMID 26047975. S2CID 7540974.
Barkowski RS, Frishman WH (May 2018). "HDL metabolism and CETP inhibition". Cardiology in Review. 16 (3): 154–162. doi:10.1097/CRD.0b013e31816a3b60. PMID 18414186. S2CID 25024920.